Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study
- PMID: 26765682
- DOI: 10.1111/bju.13410
Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study
Abstract
Objective: To study the risk of serial prostate biopsies on complications in men on active surveillance (AS) and determine the effect of complications on receiving further biopsies.
Patients and methods: In the global Prostate cancer Research International: Active Surveillance (PRIAS) study, men are prospectively followed on AS and repeat prostate biopsies are scheduled at 1, 4, and 7 years after the diagnostic biopsy, or once yearly if prostate-specific antigen-doubling time is <10 years. Data on complications after biopsy, including infection, haematuria, haematospermia, and pain, were retrospectively collected for all biopsies taken during follow-up in men from several large participating centres. Generalised estimating equations were used to test predictors of infection after biopsy. Competing risk analysis was used to compare the rates of men receiving further biopsies between men with and without previous complications.
Results: In all, 2 184 biopsies were taken in 1 164 men. Infection was reported after 55 biopsies (2.5%), and one in five men reported any form of complication. At multivariable analysis, the number of previous biopsies was not a significant predictor of infection (odds ratio 1.04, 95% confidence interval 0.76-1.43). The only significant predictor for infection was the type of prophylaxis used. Of all men with a complication at the diagnostic or first repeat biopsy, 21% did not have a repeat biopsy at the time a repeat biopsy was scheduled according to protocol, vs 12% for men without a previous biopsy complication.
Conclusion: In our present cohort of men on AS, we found no evidence that repeat prostate biopsy in itself posed a risk of infection. However, complications after biopsy were not uncommon and after a complication men were less likely to have further biopsies. We should aim to safely reduce the amount of repeat biopsies in men on AS.
Keywords: active surveillance; biopsy; complication; infection; perineal; prostatic neoplasms.
© 2016 The Authors BJU International © 2016 BJU International Published by John Wiley & Sons Ltd.
Comment in
-
Active surveillance for prostate cancer: is it too active?BJU Int. 2016 Sep;118(3):343. doi: 10.1111/bju.13473. BJU Int. 2016. PMID: 27524716 No abstract available.
Similar articles
-
Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.Eur Urol. 2015 Nov;68(5):814-21. doi: 10.1016/j.eururo.2015.06.012. Epub 2015 Jun 29. Eur Urol. 2015. PMID: 26138043
-
Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols.BJU Int. 2015 Feb;115(2):216-22. doi: 10.1111/bju.12828. Epub 2014 Aug 16. BJU Int. 2015. PMID: 24904995
-
The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study.Int J Clin Oncol. 2020 Dec;25(12):2107-2114. doi: 10.1007/s10147-020-01761-3. Epub 2020 Aug 8. Int J Clin Oncol. 2020. PMID: 32770439
-
The Prostate cancer Research International: Active Surveillance study.Curr Opin Urol. 2012 May;22(3):216-21. doi: 10.1097/MOU.0b013e328351dcc7. Curr Opin Urol. 2012. PMID: 22453333 Review.
-
The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation.Arch Pathol Lab Med. 2014 Oct;138(10):1387-405. doi: 10.5858/arpa.2014-0219-SA. Epub 2014 Aug 5. Arch Pathol Lab Med. 2014. PMID: 25092589 Review.
Cited by
-
Long-term outcomes of the first prospective study of active surveillance for prostate cancer in Japan.Int J Clin Oncol. 2024 Aug 1. doi: 10.1007/s10147-024-02590-4. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39085727
-
Reliability of Multiparametric Magnetic Resonance Imaging in Patients with a Previous Negative Biopsy: Comparison with Biopsy-Naïve Patients in the Detection of Clinically Significant Prostate Cancer.Diagnostics (Basel). 2023 Jun 1;13(11):1939. doi: 10.3390/diagnostics13111939. Diagnostics (Basel). 2023. PMID: 37296791 Free PMC article.
-
Active Surveillance for Prostate Cancer: Past, Current, and Future Trends.J Pers Med. 2023 Apr 3;13(4):629. doi: 10.3390/jpm13040629. J Pers Med. 2023. PMID: 37109015 Free PMC article. Review.
-
Clinical Value of a Routine Urine Culture Prior to Transrectal Prostate Biopsy.Eur Urol Open Sci. 2022 Dec 26;48:54-59. doi: 10.1016/j.euros.2022.11.024. eCollection 2023 Feb. Eur Urol Open Sci. 2022. PMID: 36743399 Free PMC article.
-
The transition from transrectal to transperineal prostate biopsy without antibiotic prophylaxis: Cancer detection rates and complication rates.Prostate Cancer Prostatic Dis. 2023 Sep;26(3):581-587. doi: 10.1038/s41391-022-00641-3. Epub 2023 Jan 11. Prostate Cancer Prostatic Dis. 2023. PMID: 36631536
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials